AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 165 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,935,383 | -28.2% | 1,775,167 | -17.8% | 0.05% | -25.7% |
| Q2 2023 | $61,187,512 | +45.0% | 2,160,576 | +17.6% | 0.07% | +42.9% |
| Q1 2023 | $42,210,062 | -7.8% | 1,837,617 | +12.7% | 0.05% | -9.3% |
| Q4 2022 | $45,788,811 | -18.5% | 1,630,826 | -17.9% | 0.05% | -26.0% |
| Q3 2022 | $56,169,000 | +46.5% | 1,986,165 | +14.8% | 0.07% | +55.3% |
| Q2 2022 | $38,346,000 | -18.4% | 1,729,654 | +7.2% | 0.05% | -2.1% |
| Q1 2022 | $46,967,000 | +12.6% | 1,613,429 | +27.2% | 0.05% | +17.1% |
| Q4 2021 | $41,695,000 | -17.9% | 1,268,470 | +15.2% | 0.04% | -25.5% |
| Q3 2021 | $50,801,000 | -38.4% | 1,100,783 | -26.4% | 0.06% | -38.2% |
| Q2 2021 | $82,450,000 | +2.4% | 1,496,096 | -4.1% | 0.09% | -9.2% |
| Q1 2021 | $80,533,000 | +2.0% | 1,559,501 | -14.4% | 0.10% | -6.7% |
| Q4 2020 | $78,964,000 | +25.0% | 1,822,381 | +0.9% | 0.10% | +4.0% |
| Q3 2020 | $63,194,000 | -25.7% | 1,805,542 | +13.5% | 0.10% | -31.3% |
| Q2 2020 | $85,054,000 | +91.3% | 1,590,391 | +26.9% | 0.15% | +45.5% |
| Q1 2020 | $44,456,000 | -39.3% | 1,252,994 | -18.3% | 0.10% | -19.2% |
| Q4 2019 | $73,237,000 | +74.5% | 1,533,749 | +18.4% | 0.12% | +58.2% |
| Q3 2019 | $41,959,000 | -53.0% | 1,295,021 | -27.7% | 0.08% | -53.0% |
| Q2 2019 | $89,291,000 | -25.4% | 1,790,126 | +0.9% | 0.17% | -29.4% |
| Q1 2019 | $119,649,000 | +92.2% | 1,774,158 | +31.4% | 0.24% | +60.8% |
| Q4 2018 | $62,259,000 | -30.5% | 1,350,227 | +16.2% | 0.15% | -11.4% |
| Q3 2018 | $89,614,000 | +45.4% | 1,162,010 | +58.8% | 0.17% | +30.5% |
| Q2 2018 | $61,639,000 | +11.5% | 731,794 | +8.3% | 0.13% | +0.8% |
| Q1 2018 | $55,263,000 | +18.8% | 675,756 | -16.9% | 0.13% | +14.4% |
| Q4 2017 | $46,516,000 | +8.2% | 813,647 | +26.3% | 0.11% | 0.0% |
| Q3 2017 | $43,008,000 | -14.2% | 644,316 | -33.8% | 0.11% | -17.2% |
| Q2 2017 | $50,106,000 | +34.1% | 973,870 | +52.3% | 0.13% | +28.8% |
| Q1 2017 | $37,351,000 | +64.9% | 639,579 | +17.8% | 0.10% | +55.2% |
| Q4 2016 | $22,654,000 | -34.1% | 542,867 | -16.5% | 0.07% | -35.0% |
| Q3 2016 | $34,351,000 | +38.7% | 650,332 | +10.0% | 0.10% | +32.1% |
| Q2 2016 | $24,763,000 | +1.2% | 591,071 | -1.9% | 0.08% | -1.3% |
| Q1 2016 | $24,474,000 | -74.2% | 602,817 | -58.8% | 0.08% | -68.0% |
| Q4 2015 | $95,039,000 | -17.1% | 1,463,946 | -9.8% | 0.25% | -25.6% |
| Q3 2015 | $114,598,000 | -4.5% | 1,623,430 | +50.4% | 0.33% | +6.8% |
| Q2 2015 | $119,952,000 | – | 1,079,286 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |